Predictive Value of Two Polymorphisms of ERCC2, rs13181 and rs1799793, in Clinical Outcomes of Chemotherapy in Gastric Cancer Patients: A Meta-Analysis

Table 2

Characteristics of eligible studies included in this meta-analysis.

Number

Study

Year

Country

Ethnicity

Number of patients

Age

Cancer types

Chemotherapeutic

TNM stage

Evaluation criterion

Outcomes

ERCC2 rs13181

ERCC2 rs1799793

AA

AC

CC

AC + CC

GG

GA

AA

GA + AA

1

Zheng

2016

China

Asia

224

57.4 ± 9.20

Gastric cancer

Platinum-based chemotherapy

I-IV

WHO

ORR

77/39^a

51/33^a

14/10^a

_

82/42^a

46/30^a

14/10^a

_

2

Mo

2015

China

Asia

228

56.65 ± 11.52

Gastric cancer

Platinum-based chemotherapy oxaliplatin

I-IV

RECIST

ORR

82/34^a

54/29^a

17/12^a

71/41^a

87/38^a

56/29^a

10/8^a

66/37^a

3

Yu

2015

China

Asia

346

64.5 ± 9.2

Gastric cancer

Fluorouracil (5FU) and folinic acid chemotherapy

NR

WHO

ORR

141/107^a

_

_

66/32^a

88/79^a

_

_

119/60^a

4

Zhong

2015

China

Asia

263

62.40 ± 9.50

Gastric cancer

FOLFOX chemotherapy

I-IV

WHO

ORR

_

_

_

_

86/57^a

57/45^a

9/9^a

66/54^a

5

Ding

2015

China

Asia

380

58.7 ± 16.3

Gastric cancer

Platinum-based chemotherapy

I-IV

WHO

ORR

92/67^a

_

_

131/90^a

86/79^a

_

_

137/78^a

7

Xue

2015

China

Asia

410

63.7 ± 11.4

Gastric cancer

FOLFOX chemotherapy

I-IV

WHO

ORR

89/69^a

123/52^a

57/20^a

_

108/66^a

123/65^a

37/11^a

_

8

Yu

2015

China

Asia

228

55.7 ± 13.8

Gastric cancer

FOLFOX chemotherapy

I-IV

WHO

ORR

86/50^a

46/32^a

7/7^a

_

79/42^a

54/38^a

6/9^a

_

9

Zhou

2014

China

Asia

415

56.2 ± 15.6

Gastric cancer

Platinum-based chemotherapy

I-IV

WHO

ORR

139/109^a

74/52^a

25/16^a

_

130/119^a

67/46^a

41/12^a

_

11

Goekkurt

2009

Germany

Caucasian

156

64 (27–86)

Gastric cancer

FU and platinum-based

NR

WHO

ORR

66/91^a

60/90^a

36/88^a

_

70/82^a

48/123^a

60/60^a

_

12

Keam

2008

South Korea

Asia

73

59 (24–77)

Gastric cancer

FOLFOX chemotherapy

NR

WHO

ORR

28/4^a

_

_

34/7^a

1/7^a

31/34^a

_

_

13

Ruzzo

2006

Italy

Caucasian

175

61 (38–79)

Gastric cancer

Fluorouracil/cisplatin palliative chemotherapy

I-IV

RECIST

ORR

17/37^a

36/54^a

17/14^a

_

13/34^a

36/52^a

21/19^a

_

NR: not reported; ORR: objective response rate; OS: overall survival; RECIST: Response Evaluation Criteria in Solid Tumors; WHO: World Health Organization; ^anumber of patients for ORR; in front of oblique line is responders (complete response (CR) + partial response (PR)) and behind oblique line is nonresponder (stable disease (SD) + progressive disease (PD)).